Physician's First Watch Archive

Medical news from NEJM Journal Watch

July 28, 2015

By Kelly Young

Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD

The FDA is examining the potential risks associated with brain deposits that may occur after repeated use of gadolinium-based contrast …

By Kristin J. Kelley

Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD

All adults should be screened for depression in primary care settings "with adequate systems in place to ensure …

By Kelly Young

Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD

The 2015 American Board of Internal Medicine's Maintenance of Certification program could cost physicians an average of …

By Jenni Whalen

Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD

Children who have otitis media with effusion may benefit from autoinflation with a nasal balloon device, according a study in the Canadian Medical Association Journal.

Approximately 300 U.K. …

By the Editors

NEJM Group offers so many valuable resources for practicing clinicians. Here's what we chose for you today:

NEJM Clinical Practice Center: Review Article: This review summarizes recent innovations in the …

By Amy Orciari Herman

Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD

A new study, published in the Annals of Internal Medicine, adds to the evidence suggesting that wide variability in blood pressure …

July 27, 2015

By Kelly Young

Edited by Susan Sadoughi, MD

The FDA has approved alirocumab (Praluent) as an adjunctive therapy to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (e.g., myocardial infarction or …

By the Editors

The FDA has approved a new assay that will detect HIV-1 antibodies, HIV-2 antibodies, and HIV-1 p24 …

By the Editors

The FDA has proposed including the percent daily value for added sugars to nutrition labels of packaged …

By Kristin J. Kelley

Edited by Susan Sadoughi, MD

Sonidegib (brand name: Odomzo) has been approved for the treatment of locally advanced basal cell carcinoma. It is indicated for adults …

Pages